<?xml version="1.0" encoding="UTF-8"?>
<p>Camrelizumab is a humanized anti programmed death-1 (PD-1) monoclonal antibody. Blocking PD-1 signaling rescues exhausted CD8+T cells and restores their activity during viral infections, but lung toxicity is reported [
 <xref rid="B208-ijms-21-05559" ref-type="bibr">208</xref>]. A clinical trial has been registered using camrelizumab for treatment of critical COVID-19 patients in China [
 <xref rid="B209-ijms-21-05559" ref-type="bibr">209</xref>]. Omalizumab is an IgG1 humanized anti IgE monoclonal antibody that reduces hypersensitivity to allergens and also decreases late inflammation events, so may be considered for COVID-19 patients with dermatologic symptoms [
 <xref rid="B210-ijms-21-05559" ref-type="bibr">210</xref>].
</p>
